[go: up one dir, main page]

DK1940447T3 - Behandling af neurodegenrative lidelser - Google Patents

Behandling af neurodegenrative lidelser

Info

Publication number
DK1940447T3
DK1940447T3 DK06793581.7T DK06793581T DK1940447T3 DK 1940447 T3 DK1940447 T3 DK 1940447T3 DK 06793581 T DK06793581 T DK 06793581T DK 1940447 T3 DK1940447 T3 DK 1940447T3
Authority
DK
Denmark
Prior art keywords
treatment
neurodegenrative
disorders
neurodegenrative disorders
Prior art date
Application number
DK06793581.7T
Other languages
English (en)
Inventor
Anton Haselbeck
Joerg Huwyler
Michael Jarsch
Frank Herting
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37622051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1940447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1940447T3 publication Critical patent/DK1940447T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK06793581.7T 2005-09-28 2006-09-18 Behandling af neurodegenrative lidelser DK1940447T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108946 2005-09-28
PCT/EP2006/066438 WO2007039436A1 (en) 2005-09-28 2006-09-18 Treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
DK1940447T3 true DK1940447T3 (da) 2014-01-20

Family

ID=37622051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06793581.7T DK1940447T3 (da) 2005-09-28 2006-09-18 Behandling af neurodegenrative lidelser

Country Status (18)

Country Link
US (2) US20070072795A1 (da)
EP (1) EP1940447B1 (da)
JP (1) JP5096345B2 (da)
KR (1) KR20080038440A (da)
CN (1) CN101277715B (da)
AR (1) AR055654A1 (da)
AU (1) AU2006298826B2 (da)
BR (1) BRPI0616572A2 (da)
CA (1) CA2622609A1 (da)
DK (1) DK1940447T3 (da)
ES (1) ES2445035T3 (da)
IL (1) IL189853A (da)
PL (1) PL1940447T3 (da)
RU (1) RU2467761C2 (da)
SI (1) SI1940447T1 (da)
TW (1) TWI380824B (da)
WO (1) WO2007039436A1 (da)
ZA (1) ZA200802270B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
RU2515914C1 (ru) * 2013-02-12 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика" Гибридный белок на основе рекомбинантного эритропоэтина человека, обладающий пролонгированным действием (варианты), и способ его получения
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644077A (en) * 1898-08-01 1900-02-27 Farbenfabriken Of Elberfeld Company Acetyl salicylic acid.
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
KR100883232B1 (ko) * 1999-04-13 2009-02-10 케네쓰 에스 워렌 래보러토리즈 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능 조절법
US6225895B1 (en) * 1999-05-26 2001-05-01 Floyd E. Bigelow, Jr. Towed vehicle monitor system
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU784091B2 (en) * 2000-05-15 2006-02-02 F. Hoffmann-La Roche Ag New pharmaceutical composition
EP1298994A2 (en) * 2000-07-10 2003-04-09 NAITO, Albert T. Method for opening the blood-brain barrier
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
EP1345628B1 (en) * 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
CA2488497A1 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
MXPA05012515A (es) * 2003-05-19 2006-05-25 Kenneth S Warren Inst Inc Citocinas protectoras de tejido para la proteccion, restablecimiento y potenciacion de celulas, tejidos y organos sensibles, con una ventana terapeutica ampliada.
CN1901934B (zh) * 2003-12-19 2013-09-11 弗·哈夫曼-拉罗切有限公司 促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途
DE602006018334D1 (de) * 2005-09-28 2010-12-30 Hoffmann La Roche Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Also Published As

Publication number Publication date
KR20080038440A (ko) 2008-05-06
IL189853A (en) 2012-06-28
BRPI0616572A2 (pt) 2009-11-24
ES2445035T3 (es) 2014-02-27
PL1940447T3 (pl) 2014-04-30
CA2622609A1 (en) 2007-04-12
TW200727911A (en) 2007-08-01
CN101277715A (zh) 2008-10-01
CN101277715B (zh) 2013-03-27
RU2467761C2 (ru) 2012-11-27
AU2006298826B2 (en) 2010-04-01
AU2006298826A1 (en) 2007-04-12
JP2009510008A (ja) 2009-03-12
WO2007039436A1 (en) 2007-04-12
ZA200802270B (en) 2009-02-25
JP5096345B2 (ja) 2012-12-12
EP1940447B1 (en) 2013-11-27
US20100267632A1 (en) 2010-10-21
SI1940447T1 (sl) 2014-03-31
RU2008116309A (ru) 2009-11-10
TWI380824B (zh) 2013-01-01
EP1940447A1 (en) 2008-07-09
IL189853A0 (en) 2008-11-03
AR055654A1 (es) 2007-08-29
US20070072795A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
DK1890684T3 (da) Behandling af søvn/vågenhedsforstyrrelser
DK1720866T3 (da) Fremgangsmåde
EP1845849A4 (en) EXISCELET FOR THE LEGS
EP1874239A4 (en) HALF-POWERED EXOSCELETT OF LOWER EXTREMITY
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1938528T3 (da) Provision af qos-behandling baseret på flere anmodninger
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1869025T6 (da) Piperazin-substituerede benzothiophener til behandling af mentale lidelser
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
NO20070251A (no) Brønnbehandling
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
FI20060708L (fi) Hierontalaite
DK1802579T3 (da) Derivater af 3-arylaminopyridin
PT1928223E (pt) Singularizador de sementes
NO20070297A (no) Brønnbehandling
CY2200156T2 (el) Επεξεργασια λυματων
DK1945277T3 (da) Opretholdelse af desinfektion af medicinsk udstyr
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1962869T3 (da) Behandling af luftvejssygdomme
DK1907374T3 (da) Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos